Axcella Health Analyst Ratings
Axcella Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2022 | 367.29% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 834.58% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 647.66% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 460.75% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 554.21% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 741.12% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 1021.5% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 460.75% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 367.29% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 1208.41% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 834.58% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 1395.33% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 834.58% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 1208.41% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 834.58% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 2236.45% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 2516.82% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 1769.16% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 834.58% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 928.04% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 1769.16% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 2236.45% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/02/2022 | 367.29% | 查丹資本 | 7 美元 → 5 美元 | 維護 | 購買 |
| 2022 年 3 月 10 日 | 834.58% | HC Wainwright & Co. | 8 美元 → 10 美元 | 維護 | 購買 |
| 08/03/2022 | 647.66% | HC Wainwright & Co. | 14 美元 → 8 美元 | 維護 | 購買 |
| 08/03/2022 | 460.75% | SVB Leerink | 9 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 05/09/2022 | 554.21% | 查丹資本 | 12 美元 → 7 美元 | 維護 | 購買 |
| 03/31/2022 | 741.12% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 11/16/2021 | 1021.5% | 查丹資本 | 10 美元 → 12 美元 | 維護 | 購買 |
| 2021 年 12 月 10 日 | 460.75% | 貴族資本市場 | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 9 月 22 日 | 367.29% | 高盛 | 9 美元 → 5 美元 | 降級 | 買入 → 中性 |
| 07/30/2021 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 2021 年 6 月 7 日 | 1208.41% | HC Wainwright & Co. | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/03/2021 | 834.58% | 查丹資本 | 16 美元 → 10 美元 | 維護 | 購買 |
| 10/27/2020 | 1395.33% | 查丹資本 | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/26/2020 | 834.58% | SVB Leerink | → 10 美元 | 假設 | → 跑贏大盤 |
| 2020 年 9 月 25 日 | 1208.41% | B. 萊利證券 | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/06/2020 | 834.58% | SVB Leerink | 20 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 07/31/2020 | 2236.45% | 派珀·桑德勒 | → 25 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/28/2020 | 2516.82% | Wedbush | → 28 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2020 年 5 月 18 日 | 1769.16% | SVB Leerink | 21 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 05/01/2020 | 834.58% | BTIG | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/15/2019 | 928.04% | 摩根大通 | 20 美元 → 11 美元 | 維護 | 超重 |
| 06/03/2019 | 1769.16% | 摩根大通 | → 20 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/03/2019 | 2236.45% | 高盛 | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Axcella Health Questions & Answers
Axcella 健康問題與解答
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by Chardan Capital on November 2, 2022. The analyst firm set a price target for $5.00 expecting AXLA to rise to within 12 months (a possible 367.29% upside). 7 analyst firms have reported ratings in the last year.
查丹資本於2022年11月2日公佈了Axcella Health（納斯達克股票代碼：AXLA）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計AXLA將在12個月內上漲至5.00美元（可能上漲367.29％）。去年有7家分析公司公佈了評級。
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by Chardan Capital, and Axcella Health maintained their buy rating.
Axcella Health（納斯達克股票代碼：AXLA）的最新分析師評級由Chardan Capital提供，Axcella Health維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Axcella Health的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Axcella Health的最後一次評級是在2022年11月2日提交的，因此您應該預計下一個評級將在2023年11月2日左右公佈。
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a maintained with a price target of $7.00 to $5.00. The current price Axcella Health (AXLA) is trading at is $1.07, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但Axcella Health（AXLA）的最新評級維持不變，目標股價爲7.00美元至5.00美元。Axcella Health（AXLA）目前的交易價格爲1.07美元，超出了分析師的預期區間。